CHESTERBROOK, Pa., Oct. 12, 2018 (GLOBE NEWSWIRE) — Trevena, Inc. (NASDAQ: TRVN) today appear a affiche presentation at ANESTHESIOLOGY® 2018, the civic appointment for the American Society of Anesthesiologists (ASA), demography abode in San Francisco, CA, from October 13 – 17, 2018.
The affiche presentation highlights abstracts from a large, open-label assurance abstraction evaluating oliceridine beneath altitude advised to challenge real-world convenance in hospital patients with abstinent to astringent astute affliction astute intravenous (IV) opioids beyond a ample spectrum of surgical and medical conditions.
“There are cogent challenges with accepted IV opioids in arresting the antithesis amid award able affliction abatement and aspersing treatment-limiting ancillary effects,” said Harold S. Minkowitz, M.D., Associate Director, Analytic Research, Division of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Centre. “There accept been actual few new analgesic options in decades. The abstracts from this abstraction suggests that oliceridine, if approved, may be an important new analysis advantage in lieu of accepted IV opioids.”
Poster presentation: Sunday, October 14th
In the ATHENA open-label assurance study, oliceridine was administered to 768 patients with abstinent to astringent astute affliction acquired by medical altitude or anaplasty beyond 41 sites in the United States. The balloon included abundant representation of patients at animated accident for opioid-related adverse contest (ORAEs), with 32% of patients over 65 years old, and added than 50% with anatomy accumulation basis (BMI) over 30 kg/m2. After-effects of the balloon showed that the assurance contour of oliceridine, in a broader accommodating group, is like that accustomed in the controlled Phase 2 and 3 studies of oliceridine.
About OliceridineOliceridine is a G-protein biased mu-opioid receptor (MOR) ligand in development for the administration of abstinent to astringent astute affliction in hospitals or added controlled analytic settings and area intravenous (IV) analysis is warranted. It is a new actinic article with a atypical apparatus of activity that enables added careful targeting of anew apparent pathways with the abeyant for beneath ancillary effects. Oliceridine is an investigational artefact and has not been accustomed by the FDA or any added authoritative agency. If approved, the Aggregation has requested that oliceridine be classified as a Schedule II controlled substance.
About Trevena Trevena, Inc. is a biopharmaceutical aggregation focused on the development and commercialization of new and avant-garde analysis options for patients in pain. The Aggregation has apparent three atypical and differentiated biologic candidates application its proprietary platform, including intravenous (IV) oliceridine, for the administration of abstinent to astringent astute affliction in hospitals, TRV250 for the analysis of astute migraine, and TRV734 for affliction and/or administration of opioid dependence. In its preclinical programs, Trevena is evaluating a set of atypical S1P modulators that may action a new, non-narcotic access to managing abiding pain.
Cautionary agenda on advanced attractive statements Any statements in this columnist absolution about approaching expectations, affairs and affairs for the Company, including statements about the Company’s strategy, approaching operations, analytic development of its ameliorative candidates, affairs for abeyant approaching artefact candidates and added statements absolute the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and agnate expressions, aggregate advanced statements aural the acceptation of The Private Securities Litigation Reform Act of 1995. Actual after-effects may alter materially from those adumbrated by such advanced statements as a aftereffect of assorted important factors, including: the status, timing, costs, after-effects and estimation of the Company’s analytic trials or any approaching trials, including whether the abstracts from the ATHENA open-label assurance abstraction advance that oliceridine, if approved, may be an important new analysis advantage in lieu of accepted opioids; the uncertainties inherent in administering analytic trials; interpretations of authoritative interactions and expectations for authoritative submissions and approvals; availability of allotment acceptable for the Company’s accountable and adventitious operating costs and basic amount requirements; uncertainties accompanying to the Company’s bookish property; added affairs that could affect the availability or bartering abeyant of the Company’s ameliorative candidates; and added factors discussed in the Accident Factors set alternating in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in added filings the Aggregation makes with the SEC from time to time. In addition, the advanced statements included in this columnist absolution represent the Company’s angle alone as of the date hereof. The Aggregation anticipates that consecutive contest and developments may account the Company’s angle to change. However, while the Aggregation may accept to amend these advanced statements at some point in the future, it accurately disclaims any obligation to do so, except as may be appropriate by law.
Investors:Jonathan Violin, Ph.D.Senior Vice President, Scientific Affairs & Investor Relations Officer610-354-8840 email@example.com
Learn All About Iv Medication Labeling Requirements From This Politician | Iv Medication Labeling Requirements – iv medication labeling requirements
| Encouraged to my website, in this period I’ll explain to you regarding iv medication labeling requirements